COMMUNIQUÉS West-GlobeNewswire

Peptides Canada Operated by Growth Guys Announces Launch of Domestic Research Peptide Supply Platform
06/10/2026
TORONTO, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Peptides Canada , operated by Growth Guys, today announced the launch of its Canadian research-peptide supply platform , providing a domestic online source for peptide [...]
Nox Peptides Announces Expanded Research Focus on BPC-157 as Canadian Peptide Research Supply Demand Grows
06/10/2026
Toronto, ON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Nox Peptides today announced an expanded focus on providing information and access to research peptide supplies for Canadian laboratories, academic researchers and [...]
Communiqué de presse : Mise en ligne du document «Q3 2026 aide-mémoire »
06/10/2026
Mise en ligne du document «Q3 2026 aide-mémoire » Paris, France – 6 octobre 2026 . Sanofi annonce la mise en ligne de son « Q3 2026 aide-mémoire » sur la page « Investisseurs » de sanofi.com. Résultats du troisième [...]
Press Release : Availability of the aide-mémoire for Q3 2026 results
06/10/2026
Availability of the aide-mémoire for Q3 2026 results Paris, France – October 6, 2026 . Sanofi announced today the availability of the aide-mémoire for Q3 2026 results on the "Investors" page of sanofi.com: Third quarter [...]
Kylo Peptides Review Brings Transparency to the Research Peptide Market
06/10/2026
Review highlights testing documentation, lot-specific COAs, independent laboratory analysis, and supplier information to help researchers evaluate research peptide sources. Sheridan, Wyoming, Oct. 06, 2026 (GLOBE [...]
Bulk Peptides: Kylo Peptides Launches Bulk Research Program for High-Volume Laboratories
06/10/2026
Sheridan, Wyoming, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Kylo Peptides [ https://kylopeptides.com/ ] has introduced a research program that supplies bulk peptides to laboratories with higher-volume peptide requirements. It [...]
Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market
06/10/2026
ORION CORPORATION PRESS RELEASE 6 OCTOBER 2026 at 9.00 EEST Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market Orion Corporation (“Orion Pharma”) and Qilu Pharma [...]
One04 Therapeutics to present late-breaking interim Phase 1 results for CPV-104 in C3 glomerulopathy at ASN Kidney Week followed by Virtual KOL Event
06/10/2026
First clinical data for CPV-104 in patients, including interim safety, tolerability and pharmacokinetics, accepted as a late-breaking poster Expert panel to join One04 management in a virtual key opinion leader (KOL) [...]
RougeTx Launches with $58 Million Series A Financing to Advance First-in-Class Treatment for Hereditary Hemorrhagic Telangiectasia
06/10/2026
Series A co-led by BioGeneration Ventures, Angelini Ventures and Kurma Partners, with participation from Epidarex Capital, Vesalius Biocapital Partners, ROM Utrecht Region, p53 Invest and Kerna Ventures. Financing will [...]
Rewind Therapeutics Secures Additional Financing to Advance Oral GPR17 Remyelination Program
06/10/2026
Financing will be used to advance Rewind's lead oral program designed to promote remyelination and restore neurological function Peer-reviewed data published in PLOS ONE demonstrated remyelination and functional [...]
RQ Bio Appoints Gavin Koh as Chief Medical Officer and Strengthens Leadership to Advance RQB01
06/10/2026
Dr Koh brings extensive infectious disease and clinical development expertise as RQ Bio prepares to advance RQB01 into the clinic Senior appointments across CMC, clinical operations and programme management further [...]
Angelini Ventures and EIB Co-lead $58 Million Series A Financing in Rouge Therapeutics to Advance First-in-Class Treatment for Hereditary Hemorrhagic Telangiectasia
06/10/2026
Marks the fourth investment completed under Angelini Ventures’ €150 million co-investment partnership with the European Investment Bank in less than 12 months Regina Hodits from Angelini Ventures to join Rouge [...]
Resolution Therapeutics to present interim Phase I/II EMERALD study data on RTX001 as a late-breaker at AASLD 2026
06/10/2026
Interim data from Phase I/II EMERALD study for RTX001, Resolution’s engineered Regenerative Macrophage Therapy, accepted as late-breaking presentation Dr. Lara Campana to present preclinical data on intravenous [...]
Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock
06/10/2026
WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate [...]
Major shareholder announcement - BlackRock, Inc.
05/10/2026
ANNOUNCEMENT NO. 318 5 October 2026 Pursuant to section 30 of the Danish Capital Markets Act, notice is hereby given that BlackRock, Inc. has notified ChemoMetec that, on 29 September 2026, BlackRock, Inc. increased its [...]
ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development
05/10/2026
ORIC-259 is a potential first-in-class small molecule mRNA degrader targeting CIP2A, a previously undruggable target Cancer Research UK to fully fund, sponsor, design, and execute CTA-enabling studies and Phase 1/2 [...]
iCell Gene Therapeutics Announces Upcoming Conference Presentations
05/10/2026
STONY BROOK, N.Y., Oct. 05, 2026 (GLOBE NEWSWIRE) -- iCell Gene Therapeutics ("iCell Gene"), a clinical-stage biopharmaceutical company developing autologous and in vivo CAR T cell therapies for autoimmune diseases and [...]
BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day
05/10/2026
- October 6 YouTube premiere featuring Sway Calloway, Howard “H” White and leading medical and cultural voices anchors community education nationwide PALO ALTO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma [...]
Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/10/2026
PHILADELPHIA, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically [...]

Pages